
    
      This study aims to investigate the therapeutic efficacy of PIPAC using doxorubicin and
      cisplatin in women with recurrent ovarian cancer and disease progression with peritoneal
      carcinomatosis. The primary objective of this study is to determine the Clinical Benefit Rate
      (CBR) according to RECIST criteria after three cycles of PIPAC with cisplatin and
      doxorubicin.
    
  